Projecten per jaar
Persoonlijk profiel
Expertise
Project: " Targeting of tumor subpopulations in Multiple Myeloma: protein/gene expression analysis of residual cancer cells and targeting of these cells using nanobodies"
I obtained a Master in Biomedical Sciences at the Free University of Brussels (Vrije Universiteit Brussel, VUB) in 2011. I started my PhD in the lab of Hematology and Immunology (HEIM) under the supervision of Prof. Karin Vanderkerken focusing on the role of the bone marrow microenvironment in multiple myeloma drug resistance. I participated in an EU FP7 project (OVER-MyR) and investigated different cell types that contribute to myeloma disease including myeloid-derived suppressor cells (supervised by Prof. Els Van Valckenborgh), cancer associated fibroblasts (supervised by Prof. Eline Menu and Prof. Angelo Vacca) and mesenchymal stromal cells (supervised by Prof. Ivan Van Riet). In 2016, I obtained a FWO grant to continue my work as a post-doctoral researcher at the HEIM department and in 2018I became assistant professor (10%) at the VUB.
My project focuses on the use of antigen-specific nanobodies to target residual disease in myeloma and prevent relapse of patients. In collaboration with Prof Peter Croucher (Garvan Institute, Sydney, Australia), we investigate myeloma cell dormancy in vitro and in vivo. Nationally, I closely collaborate with Profs Nick Devoogdt and Matthias D’Huyvetter for the development and characterization of AXL- and CS1 specific nanobodies to target minimal residual disease in myeloma by targeted radionuclide therapy (TRNT).
Vingerafdruk
Verdiep u in de onderzoeksgebieden waarop Kim De Veirman actief is. Deze onderwerplabels komen uit het werk van deze persoon. Samen vormen ze een unieke vingerafdruk.
- 1 Soortgelijke profielen
Netwerk
Recente externe samenwerking op landen-/regioniveau. Duik in de details door op de stippen te klikken of
-
HERC58: SPECY-SORT: SPEctrale flowCYtometer en celSORTer
Laoui, D., De Veirman, K., Van der Henst, C., Brunner, J., Messens, J., Raes, G., Van Ginderachter, J., Devoogdt, N., Magez, S., Remaut, H. K., Stijlemans, B., Movahedi, K., Peeters, E. & De Trez, C.
1/05/22 → 30/04/26
Project: Fundamenteel
-
OZR3941: Cofinanciering OZR FWO Hercules MZW: SPECY-SORT: SPEctrale flowCYtometer en celSORTer
Laoui, D., Van Ginderachter, J., Movahedi, K., De Veirman, K., Magez, S., De Trez, C., Stijlemans, B., Raes, G., Devoogdt, N., Messens, J., Brunner, J., Remaut, H. K., Fioravanti, A., Peeters, E. & Van der Henst, C.
16/03/22 → 16/03/25
Project: Fundamenteel
-
OZR3913: Cofinanciering OZR FWO Hercules MZW - Single-cell eiwit analyse in intacte weefsels
Movahedi, K., van Grunsven, L., Rooman, I., Van Ginderachter, J., Smolders, I., Neyns, B., Vanhaecke, T., Laoui, D., Breckpot, K., De Veirman, K., Stijlemans, B., Van Schependom, J., Magez, S., Goyvaerts, C., De Kock, J., De Leu, N., Massie, A., Hellemans, K., Spits, C., De Bundel, D., De Trez, C., Hernot, S., Van Dooren, S., Aerts, J., Staels, W. & Tuyaerts, S.
25/02/22 → 25/02/26
Project: Fundamenteel
-
FWOAL1045: Gepersonaliseerde therapie gericht tegen het AXL eiwit voor de behandeling van acute myeloide leukemie en multipel myeloom
De Veirman, K., Devoogdt, N. & Vanderkerken, K.
1/01/22 → 31/12/25
Project: Fundamenteel
Onderzoeksoutput
-
Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
Verheye, E., Melgar, J. B., Deschoemaeker, S., Raes, G., Maes, A., De Bruyne, E., Menu, E., Vanderkerken, K., Laoui, D. & De Veirman, K., 14 jan 2022, In : International Journal of Molecular Sciences. 23, 2, 904.Onderzoeksoutput: Scientific review
Open Access1 Citaat (Scopus) -
Emerging applications of nanobodies in cancer therapy
Awad, R. M., Meeus, F., Ceuppens, H., Ertveldt, T., Hanssens, H., Lecocq, Q., Mateusiak, L., Zeven, K., Valenta, H., De Groof, T. W. M., De Vlaeminck, Y., Krasniqi, A., De Veirman, K., Goyvaerts, C., D'Huyvetter, M., Hernot, S., Devoogdt, N. & Breckpot, K., 2022, In : International review of cell and molecular biology. 369, blz. 143-199 57 blz.Onderzoeksoutput: Article
-
Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach
Vlummens, P., Verhulst, S., De Veirman, K., Maes, A., Menu, E., Moreaux, J., De Bruyne, E., Hose, D., Vanderkerken, K. & Maes, K., 8 jun 2022, In : Frontiers in cell and developmental biology. 10, 879057.Onderzoeksoutput: Article
Open Access -
Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis
Oudaert, I., Satilmis, H., Vlummens, P., De Brouwer, W., Maes, A., Hose, D., De Bruyne, E., Ghesquière, B., Vanderkerken, K., De Veirman, K. & Menu, E., 1 feb 2022, In : Journal of Experimental & Clinical Cancer Research. 41, 1, blz. 45 17 blz., 45.Onderzoeksoutput: Article
Open Access -
System Xc- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance
Wang, F., Oudaert, I., Tu, C., Maes, A., Van der Vreken, A., Vlummens, P., De Bruyne, E., De Veirman, K., Wang, Y., Fan, R., Massie, A., Vanderkerken, K., Shang, P. & Menu, E., jun 2022, In : Cancer Letters. 535, 215649.Onderzoeksoutput: Article
Open Access
Prijzen
-
ASH abstract Achievement Award 2014
Kim De Veirman (Recipient), 6 dec 2014
Prijs: National/international honour
-
ASH abstract Achievement Award 2019
Kim De Veirman (Recipient), 2019
Prijs: National/international honour
-
Poster award Belgian Hematological Society 30th Annual General Meeting 2015
Kim De Veirman (Recipient), 29 jan 2015
Prijs: National/international honour
-
Prijs Dr. Karel-Lodewijk Verleysen 2018 ter bekroning van medisch onderzoekswerk aan de Vrije Universiteit Brussel
Kim De Veirman (Recipient), 9 dec 2019
Prijs: Prize (including medals and awards)
Activiteiten
-
Targeting of pyrroline-5-carboxylate reductase (PYCR) reduces drug resistance in multiple myeloma in vitro.
Inge Oudaert (Speaker), Eline Menu (Contributor), Kim De Veirman (Contributor)29 jan 2021 → 30 jan 2021Activiteit: Talk or presentation at a conference
-
AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers (ORC dag 2020)
Kim De Veirman (Speaker)16 okt 2020Activiteit: Talk or presentation at a conference
-
Bone marrow microenvironment and MGUS progression (Bari, Italy)
Kim De Veirman (Invited speaker)5 nov 2020 → 7 nov 2020Activiteit: Talk or presentation at a conference
-
AXL: A potential therapeutic target to improve chemosensitivity in Multiple Myeloma (BACR Annual Meeting 2020)
Kim De Veirman (Contributor), Niels Vandewalle (Speaker)7 feb 2020Activiteit: Talk or presentation at a conference
-
AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers
Niels Vandewalle (Contributor), Kim De Veirman (Speaker)14 feb 2020Activiteit: Talk or presentation at a conference
Scriptie
-
Assessment of antigen-binding domain parameters important for adequate CAR-T-cell activation: evaluating different SLAMF7-targeting nanobodies.
Auteur: Meeus, F., Hanssens, H., De Veirman, K. & Devoogdt, N., 19 jun 2020Begeleider: Hanssens, H. (Advisor)
Scriptie/masterproef: Master's Thesis
-
AXL and CS1: New targets in myeloma cell dormancy
Auteur: De Veirman, K. & Benalla, S., 21 jun 2018Scriptie/masterproef: Master's Thesis
-
Development of a NanoCAR approach for the treatment of multiple myeloma
Auteur: Devoogdt, N., Breckpot, K., De Veirman, K. & Hanssens, H., 2022Scriptie/masterproef: Doctoral Thesis
-
Mesenchymal Stromal Cell induced hedgehog signaling in Multiple Myeloma and its role in drug resistance
Auteur: De Veirman, K. & Terwecoren, D., 2013Scriptie/masterproef: Master's Thesis
-
Nanobody-based individualized AXL targeting to reverse immune suppression and overcome therapy resistance in Acute Myeloid Leukemia.
Auteur: De Veirman, K., Breckpot, K., Devoogdt, N. & Kerre, T., 2024Scriptie/masterproef: Doctoral Thesis